​

Edgewise Therapeutics Stock (NASDAQ:EWTX)

ForecastOwnershipFinancialsChart
Edgewise Therapeutics by TradingView

Previous Close

$39.99

52W Range

$15.23 - $48.51

50D Avg

$41.84

200D Avg

$35.93

Market Cap

$4.23B

Avg Vol (3M)

$1.44M

Beta

0.28

Div Yield

-

EWTX Company Profile

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

127

IPO Date

Mar 26, 2021

Website

EWTX Performance

EWTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-191.41M$-158.83M$-114.36M
Net Income$-167.79M$-133.81M$-100.16M
EBITDA$-191.41M$-156.54M$-112.63M
Basic EPS$-1.63$-1.45$-1.57
Diluted EPS$-1.63$-1.45$-1.57

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
STOKStoke Therapeutics, Inc.
CAPRCapricor Therapeutics, Inc.
SLDBSolid Biosciences Inc.
PEPGPepGen Inc.
SRPTSarepta Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
LRMRLarimar Therapeutics, Inc.
DYNDyne Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.